| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
91,540,000 |
| Market
Cap: |
34.79(M) |
| Last
Volume: |
1,296,467 |
Avg
Vol: |
1,292,849 |
| 52
Week Range: |
$0.38 - $0.9341 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Curis is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Co.'s clinical stage drug candidates are: Emavusertib, which is being tested in a Phase 1/2 dose escalating clinical trial in patients with non-Hodgkin lymphomas; CI-8993, which is a monoclonal antibody; Fimepinostat, which is a small molecule that potently inhibits the activity of histone deacetylase, and phosphotidyl-inositol 3 kinase; CA-170, for which Co. has announced initial data from a clinical study in patients with mesothelioma in conjunction with the Society of lmmunotherapy of Cancer; and CA-327, which is a small molecule antagonist of PDL1 and TIM3.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dentzer James E |
President & CEO |
• • – |
2022-01-31 |
4 |
AS |
$3.07 |
$9,499 |
D/D |
(3,094) |
64,877 |
|
-67% |
|
| Dentzer James E |
President & CEO |
• • – |
2022-01-27 |
4 |
AS |
$3.18 |
$7,651 |
D/D |
(2,406) |
67,971 |
|
-66% |
|
| Dentzer James E |
President & CEO |
• • – |
2021-01-26 |
4 |
AS |
$10.59 |
$32,758 |
D/D |
(3,094) |
67,268 |
|
47% |
|
| Dentzer James E |
President & CEO |
• • – |
2021-01-25 |
4 |
AS |
$10.96 |
$25,022 |
D/D |
(2,283) |
70,362 |
|
40% |
|
| Dentzer James E |
President & CEO |
• • – |
2020-01-24 |
4 |
AS |
$1.64 |
$5,076 |
D/D |
(3,094) |
42,158 |
|
-49% |
|
| Dentzer James E |
President & CEO |
• • – |
2020-01-23 |
4 |
AS |
$1.69 |
$6,182 |
D/D |
(3,658) |
45,252 |
|
-51% |
|
| Steinkrauss William |
VP, Finance & TreasurerOfficer |
• – – |
2019-03-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,767 |
|
- |
|
| Dentzer James E |
President & CEO |
• • – |
2019-01-24 |
4 |
AS |
$1.16 |
$3,577 |
D/D |
(3,094) |
41,639 |
|
- |
|
| Kaitin Kenneth I |
Director |
– • – |
2019-01-23 |
4 |
AS |
$1.05 |
$15,587 |
D/D |
(14,800) |
28,121 |
|
- |
|
| Kunkel Lori Anne |
Director |
– • – |
2019-01-23 |
4 |
AS |
$1.05 |
$15,581 |
D/D |
(14,800) |
22,200 |
|
- |
|
| Rubin Marc |
Director |
– • – |
2019-01-23 |
4 |
AS |
$1.05 |
$19,477 |
D/D |
(18,500) |
28,819 |
|
- |
|
| Greenacre Martyn D |
Director |
– • – |
2019-01-23 |
4 |
AS |
$1.05 |
$19,475 |
D/D |
(18,500) |
26,089 |
|
- |
|
| Dentzer James E |
President & CEO |
• • – |
2019-01-23 |
4 |
AS |
$1.09 |
$2,613 |
D/D |
(2,397) |
44,733 |
|
- |
|
| Martell Robert |
Head of Research & Development |
• – – |
2019-01-23 |
4 |
AS |
$1.07 |
$5,900 |
D/D |
(5,500) |
23,027 |
|
- |
|
| Martell Robert |
Head of Research & Development |
• – – |
2019-01-23 |
4 |
D |
$1.07 |
$9,066 |
D/D |
(8,473) |
28,527 |
|
- |
|
| Martell Robert |
Director |
– • – |
2018-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
185,000 |
185,000 |
|
- |
|
| Tuck David |
Chief Medical Officer |
• – – |
2018-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
133,750 |
169,424 |
|
- |
|
| Kaitin Kenneth I |
Director |
– • – |
2018-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
185,000 |
214,607 |
|
- |
|
| Dentzer James E |
Chief Financial Officer |
• – – |
2018-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
206,250 |
212,011 |
|
- |
|
| Rubin Marc |
Director |
– • – |
2018-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
185,000 |
236,596 |
|
- |
|
| Kunkel Lori Anne |
Director |
– • – |
2018-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
185,000 |
185,000 |
|
- |
|
| Greenacre Martyn D |
Director |
– • – |
2018-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
185,000 |
222,945 |
|
- |
|
| Fattaey Ali Ph.d. |
President & CEO |
• • – |
2018-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
206,250 |
322,140 |
|
- |
|
| Rubin Marc |
Director |
– • – |
2017-11-16 |
4 |
B |
$0.98 |
$24,500 |
D/D |
25,000 |
51,596 |
2.39 |
- |
|
| Fattaey Ali Ph.d. |
President & CEO |
• • – |
2017-11-15 |
4 |
B |
$1.06 |
$53,000 |
D/D |
50,000 |
115,890 |
2.81 |
- |
|
303 Records found
|
|
Page 1 of 13 |
|
|
